Company / Return on Equity (ROE)
Intellia Therapeutics, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-61.5%
FY2025
5-year range
-61.5% / -25.8%
FY2021-FY2025
Trend
-3.3%
vs FY2024
Sector context
#141 of 147
Health Care
What the data says
Intellia Therapeutics, Inc. reports negative total equity of -61.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-61.5% in FY2025 with a 5-year CAGR of -36.0%.
Declined from -45.8% to -61.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -23.1pp
- 5-Year Change
- -36.0pp
- 10-Year Change
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 147This company -61.5% Sector average -3.1%
▼
-1869.8% below sector average
Key checks
Key Insights
- Intellia Therapeutics, Inc.'s return on equity (roe) has declined for 5 consecutive years.
- In FY2025, return on equity (roe) decreased 3.3% year-over-year.
- Currently 58.3pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -61.5% | -3.3% |
| FY2024 | -59.5% | -29.9% |
| FY2023 | -45.8% | -19.4% |
| FY2022 | -38.4% | -49.0% |
| FY2021 | -25.8% | -1.1% |
| FY2020 | -25.5% | +85.5% |
| FY2019 | -175.7% | -472.1% |
| FY2018 | -30.7% | -36.7% |
| FY2017 | -22.5% | -49.0% |
| FY2016 | -15.1% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026